T14865 |
Carboprost tromethamine
|
58551-69-2
|
99.61%
|
|
Carboprost tromethamine is the synthetic 15-methyl analogue of prostaglandin F2α and it can effectively promote law contraction of the uterus and significantly r...
|
T67946 |
EP2 receptor antagonist-2
|
615273-95-5
|
99.59%
|
|
EP2 receptor antagonist-2 (CID891729) is an antagonist of EP2 receptor . EP2 receptor antagonist-2 inhibits the EP2 receptor activation induced by PGE2. EP2 rece...
|
T3S2007 |
MRE-269
|
475085-57-5
|
99.57%
|
|
MRE-269 (ACT-333679) is an orally available and long-acting prostacyclin receptor agonist prodrug. MRE-269(ACT-333679) is used for the treatment of pulmonary art...
|
TMA0536 |
2-Acetylbenzoic acid
|
577-56-0
|
99.57%
|
|
2-Acetylbenzoic acid is more potent than 2-propionyloxybenzoic acid in inhibiting platelet function and platelet prostaglandin (PG) synthesis although the potenc...
|
T2690 |
Tranilast
|
53902-12-8
|
99.57%
|
|
Tranilast (SB 252218), an antiallergic drug, suppresses lipid mediator and cytokine release from inflammatory cells, therefore utilized in the treatment of aller...
|
T21224 |
(+)-Fluprostenol
|
54276-17-4
|
99.56%
|
|
(+)-Fluprostenol (AL-5848), an analogue of prostaglandin F2 alpha, is a prostaglandin F2α receptor PTGFR agonist and decreases the expression of Oviductal glycop...
|
T7053 |
P-Hydroxycinnamic acid
|
7400-08-0
|
99.55%
|
|
p-Hydroxycinnamic acid (NSC-59260) can inhibit platelet activity, with IC50s of 371 μM, 126 μM for thromboxane B2 production and lipopolysaccharide-induced prost...
|
T0212 |
Seratrodast
|
112665-43-7
|
99.54%
|
|
Seratrodast (ABT-001) (INN), a thromboxane A2 (TXA2) receptor (TP receptor) antagonist, is mainly used in the therapy of asthma. It was the first TP receptor ant...
|
T6399 |
AZD1981
|
802904-66-1
|
99.54%
|
|
AZD1981 is an effective and specific CRTh2 (DP2) receptor antagonist (IC50: 4 nM), showing >1000-fold selectivity over more than 340 other enzymes and receptors,...
|
T1978 |
GW627368
|
439288-66-1
|
99.54%
|
|
GW627368 (GW 627368X)X is a novel, potent and selective antagonist of prostanoid EP4 receptor.
|
T11211 |
EP4 receptor antagonist 1
|
2287259-07-6
|
99.53%
|
|
EP4 receptor antagonist 1 inhibits human and mouse EP4 receptor with IC50s of 6.1 nM and 16.2 nM, respectively. IC50s >10 μM for human EP1, EP2,and EP3 receptors...
|
T68155 |
Tebufelone
|
112018-00-5
|
99.52%
|
|
Tebufelone is a potent in vitro inhibitor of CO , a novel non-steroidal anti-inflammatory drug (NSAID) belonging to the di-tert-butylphenol (DTBP) class that has...
|
TQ0292 |
Grapiprant
|
415903-37-6
|
99.49%
|
|
Grapiprant (AAT-007) is a selective EP4 receptor antagonist. Grapiprant displaces [3H]-PGE2 (1 nM) binding to dog recombinant EP4 receptor (IC50: 35 nM, Ki: 24 n...
|
T24567 |
Octimibate
|
89838-96-0
|
99.49%
|
|
Octimibate (Octimibato) is a non-prostaglandin platelet aggregation inhibitor and cyclic prostaglandin agonist.Octimibate is used in the treatment of cardiovascu...
|
T2791 |
Pectolinarin
|
28978-02-1
|
99.47%
|
|
Pectolinarin is a Cirsium isolate with anti-inflammatory activity.
|
T3306 |
PF-04418948
|
1078166-57-0
|
99.45%
|
|
PF-04418948 is a potent EP2 receptor antagonist (IC50 = 16 nM for human EP2 receptors). Displays over 2000-fold selectivity for EP2 receptors over EP1, EP3, EP4,...
|
T15681 |
L-161982
|
147776-06-5
|
99.44%
|
|
L-161982 is a selective antagonist of EP4 receptor. L-161982 could inhibit PGE2-induced ERK phosphorylation and cell proliferation of HCA-7 cells. L-161982 could...
|
T3889 |
Platycodin D
|
58479-68-8
|
99.43%
|
|
Platycodin D may stimulate TNF-α synthesis or inhibit degradation of TNF-α mRNA. Platycodin D (10/30 μM) suppresses prostaglandin E2 production in rat peritoneal...
|
TN1362 |
Afzelin
|
482-39-3
|
99.38%
|
|
Afzelin (Kaempferol-3-O-rhamnoside) has several cellular activities such as DNA-protective, antibacterial, antioxidant, and anti-inflammatory as well as UV-absor...
|
T62525 |
TP-16
|
2332972-26-4
|
99.33%
|
|
TP-16 is a novel potent and selective EP4 antagonist that blocks the function of IMCs and enhances cytotoxic T cell-mediated tumor elimination in vivo.
|